Vimarsana
Biggest News Aggregation in the World

Page 2 - Alanh Auerbach News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alanh Auerbach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alanh Auerbach Today - Breaking & Trending Today

Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above 200-Day Moving Average of $3.52 - Vimarsana News

Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above 200-Day Moving Average of $3.52

Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.52 and traded as high as $5.16. Puma Biotechnology shares last traded at $4.71, with a volume of 749,465 shares trading hands. Wall Street Analyst Weigh In Separately, […]

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference - Vimarsana News

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

Puma Biotechnology, Inc. , a biopharmaceutical company , announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company on...

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer - Vimarsana News

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Puma Biotechnology, Inc. , a biopharmaceutical company , announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic...

Puma Biotechnology Reports Third Quarter 2023 Financial Results - Vimarsana News

Puma Biotechnology Reports Third Quarter 2023 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023. Unless otherwise stated, all comparisons are for the third quarter of 2023 compared to the third quarter of 2022.Product revenue, net consist...

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting - Vimarsana News

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Puma Biotechnology, Inc. , a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head...